MedTrace Logo

Detecting Lung Cancer Based on Exhaled Breath

NCT04419207 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2236

Last updated 2022-04-20

No results posted yet for this study

Summary

Early detection is critical to improve the overall survival of lung cancer. Endogenous volatile organic compounds (VOCs) can be derived from many different metabolic pathways. On the other hand, cancer cells have different metabolism patterns compared with normal cells. Thus, detecting VOCs in exhaled breath using highly sensitive mass spectrometry would be a promising approach for lung cancer detection.

Conditions

Interventions

DIAGNOSTIC_TEST

Breath test

Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-flight mass spectrometry (HPPI-TOFMS).

Sponsors & Collaborators

  • Beijing Haidian Hospital

    collaborator OTHER

  • Aerospace 731 Hospital

    collaborator OTHER

  • Beijing Breatha Biological Technology Co., Ltd, Beijing

    collaborator UNKNOWN

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Mantang Qiu, M.D · Peking University People's Hospital Thoracic Surgery Department

  • Zuli Zhou, M.D · Peking University People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2020-12-31
Completion
2022-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04419207 on ClinicalTrials.gov